For the subgroup of eyes with initial BCVA of 20/30 to 20/40, all treatments were associated with a statistically significant improvement in BCVA and a statistically significant reduction in CMT at 1 year. The improvement in BCVA and in CMT was significantly greater with ziv-aflibercept 2.5 mg versus 1.25 mg. There were no significant differences comparing the ziv-aflibercept groups with bevacizumab.
For eyes with initial BCVA ≤20/50, all treatments resulted in significant reduction in CMT at 1 year, and the effect was significantly greater in eyes treated with ziv-aflibercept 2.5 mg versus bevacizumab.
Dr. Soheilian has no relevant financial interests to disclose.